You've been automatically redirected here from, which is now part of Proteintech Group. Click here to dismiss this alert.
  • HEK293 expressed
  • Endotoxin-free
  • Animal-component free

HumanKine® recombinant human IL-23 protein


Typically ≤ 4 ng/mL EC50

Species Reactivity




Cat no : HZ-1254


IL 23, IL 23 A, IL 23 subunit alpha, IL 23A, IL 23p19, IL23, IL-23, IL23A, IL23P19, Interleukin 23 subunit alpha, Interleukin 23 subunit p19, P19, SGRF

Technical Specifications

GeneID 51561,3593
Species human
Expression HEK293
Activity Typically ≤ 4 ng/mL EC50
Purity >95%
Endotoxin<1 EU/µg
Molecular Mass 55 kDa, heterodimer, glycosylated
Formulation 1x PBS, See Certificate of Analysis for details
Species Reactivity human, mouse

Stability and Reconstitution

Stability and Storage Lyophilized proteins are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.
Reconstitution Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein in sterile 1xPBS containing 0.1% endotoxin-free recombinant human serum albumin (HSA).


Interleukin 23 (IL-23) is a member of the IL12 cytokine family and composed of two subunits, IL12p40 and IL23p19. It is produced by antigen presenting cells and has been shown to promote the production and survival of a distinct lineage of T-cells called TH17 cells. A functional receptor for IL-23 (the IL-23 receptor) has been identified and is composed of IL-12Rβ1 and IL-23R. IL-23 is expressed chiefly by the macrophages and DCs. The IL-23R is found on memory T cells, NKT cells, macrophages, DCs, and naive T cells upon activation by TGF-βand IL-6. The main biological effects of IL-23 identified initially are stimulation of antigen presentation by DCs, T cell differentiation to Th17 cells, and production of interferon-γ (IFN-γ). IL-23 acts also as an end-stage effector cytokine through direct action on macrophages (PMID: 16393998;15657292;12023369;12610626)


IL 23, IL 23 A, IL 23 subunit alpha, IL 23A, IL 23p19, IL23, IL-23, IL23A, IL23P19, Interleukin 23 subunit alpha, Interleukin 23 subunit p19, P19, SGRF



Eur J Pharmacol

AS2762900-00, a potent anti-human IL-23 receptor monoclonal antibody, prevents epidermal hyperplasia in a psoriatic human skin xenograft model.

Authors - Haruna Sasaki-Iwaoka

Oncol Lett

IL-23 directly enhances the proliferative and invasive activities of colorectal carcinoma.

Authors - HideyukiSuzuki

Protein Eng Des Sel

AZ17: a new bispecific drug targeting IL-6 and IL-23 with potential clinical use--improves psoriasis in a human xenograft transplantation model.

Authors - KarinStenderup

Inflamm Res

Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo.

Authors - AtsuoTanimoto

Eur J Pharmacol

Generation and characterization of a potent fully human monoclonal antibody against the interleukin-23 receptor.

Authors - HarunaSasaki-Iwaoka

Int Immunopharmacol

Autonomous cure of damaged human intestinal epithelial cells by TLR2 and TLR4-dependent production of IL-22 in response to Spirulina polysaccharides.

Authors - AkiraTominaga